We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.
Management’s guidance highlighted program and regulatory milestones and specific metrics: the company has dosed >50 patients across pivotal and confirmatory studies with line-of-sight to 60 patients by mid‑2026; plans to seek potential accelerated approval in 2027 (rolling BLA possible) and expects a safety database of ~50 patients at filing and roughly 15–20 patients with 12‑month functional data by early 1H‑2027; current top‑line dataset includes 30 patients with microdystrophin biomarker data, 31 with interim safety, and 9 with 12‑month functional data (age ≥4); the pivotal met its primary endpoint with 93% (28/30) >10% microdystrophin at Week 12, 80% >40% expression, mean expression 71.1% overall and 41.6% in patients ≥8; there is a >0.9 correlation coefficient between microdystrophin and NSAA/cTAP functional measures; safety to date: 2 treatment‑related SAEs among 31 patients (one subacute myocarditis, one asymptomatic liver injury with GGT peak 123 U/L), both resolved without sequelae, no drug‑related thrombocytopenia/myositis/neurotoxicity, and mean GGT and total bilirubin remained below ULN through 12 months; additional pipeline and corporate milestones include dosing the first Phase IIb diabetic retinopathy patient in Q2‑2026 for a $100M AbbVie milestone, subretinal pivotal readouts in Q4‑2026, RGX‑121 hold lifted and CRL appeal filed, and an expectation of 3 potential approvals over the next couple of years (including 2 blockbuster opportunities).
AFFINITY DUCHENNE pivotal Phase III met its primary endpoint with high statistical significance: 93% (28 of 30 biopsied patients) exceeded the predefined microdystrophin >10% threshold. Interim safety available for 31 dosed pivotal patients.
Very high biomarker expression: 71.1% average microdystrophin across all patients, 80% of patients >40% expression, and 41.6% average expression in patients aged ≥8. Company noted among the highest vector copy numbers and product purity (cited >80% full capsids).
A highly statistically significant correlation between microdystrophin expression and functional improvement was reported: correlation coefficients >0.9 for both NSAA change from baseline and NSAA vs cTAP predicted value, supporting microdystrophin as a surrogate endpoint likely to predict clinical benefit.
Interim 12‑month functional data (9 ambulatory patients aged ≥4) showed improvement across NSAA and timed function tests versus external controls (propensity-score weighted analyses). Caregiver-reported PODCI measures also improved. Clinical investigators corroborated meaningful functional gains and real-world patient videos were shared (1–2 year improvements).
RGX-202 was described as well tolerated: of 31 dosed patients there were 2 treatment-related SAEs (both resolved without sequelae: one subacute myocarditis and one asymptomatic liver injury). No drug-related thrombocytopenia, myositis or neurotoxicity were reported. Mean GGT and total bilirubin remained stable and well below upper limits of normal across 12 months.
More than 50 patients dosed across pivotal and confirmatory studies with line of sight to dose ~60 patients by midyear. Company is planning for potential accelerated approval and commercial filing targeting 2027. Additional program highlights: retinal Phase IIb first‑patient dosing expected Q2 (triggers $100M AbbVie milestone), partial clinical hold on RGX-121 lifted, appeal of RGX-121 CRL filed, and company targeting three approvals over the next couple of years including two potential blockbusters.
Welcome, everyone, to the REGENXBIO RGX-2026 Top line Pivotal Data Webcast. At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of REGENXBIO. Please go ahead.
Good morning, and thank you for joining us today. Earlier this morning, REGENXBIO released pivotal top line data from the AFFINITY DUCHENNE trial of RGX-2026 as well as financial and operating results for the first quarter ended March 31, 2026. The press releases are available on our website at www.regenxbio.com. Today's webcast will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management's Discussion and Analysis sections of REGENXBIO's annual report on Form 10-K for the full year ended December 31, 2025, and comparable Risk Factors sections of REGENXBIO's quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, May 14, 2026, and we undertake no obligation to update any forward-looking statemen...